TY - JOUR
T1 - Cortical microstructure in primary progressive aphasia :
T2 - a multicenter study
AU - Illán-Gala, Ignacio
AU - Montal, Victor
AU - Borrego-Écija, Sergi
AU - Mandelli, Maria Luisa
AU - Falgàs, Neus
AU - Welch, Ariane E.
AU - Pegueroles, Jordi
AU - Santos-Santos, Miguel
AU - Bejanin, Alexandre
AU - Alcolea, Daniel
AU - Dols Icardo, Oriol
AU - Belbin, Olivia
AU - Sánchez-Saudinós, M. Belén
AU - Bargalló, Nuria
AU - González-Ortiz, Sofía
AU - Lladó, Albert
AU - Blesa, Rafael
AU - Dickerson, Bradford C.
AU - Rosen, Howard J.
AU - Miller, Bruce L.
AU - Lleo Bisa, Alberto
AU - Gorno-Tempini, Maria Luisa
AU - Sánchez-Valle, Raquel
AU - Fortea, Juan
PY - 2022
Y1 - 2022
N2 - Background: Cortical mean diffusivity is a novel imaging metric sensitive to early changes in neurodegenerative syndromes. Higher cortical mean diffusivity values reflect microstructural disorganization and have been proposed as a sensitive biomarker that might antedate macroscopic cortical changes. We aimed to test the hypothesis that cortical mean diffusivity is more sensitive than cortical thickness to detect cortical changes in primary progressive aphasia (PPA). Methods: In this multicenter, case-control study, we recruited 120 patients with PPA (52 non-fluent, 31 semantic, and 32 logopenic variants; and 5 GRN-related PPA) as well as 89 controls from three centers. The 3-Tesla MRI protocol included structural and diffusion-weighted sequences. Disease severity was assessed with the Clinical Dementia Rating scale. Cortical thickness and cortical mean diffusivity were computed using a surface-based approach. Results: The comparison between each PPA variant and controls revealed cortical mean diffusivity increases and cortical thinning in overlapping regions, reflecting the canonical loci of neurodegeneration of each variant. Importantly, cortical mean diffusivity increases also expanded to other PPA-related areas and correlated with disease severity in all PPA groups. Cortical mean diffusivity was also increased in patients with very mild PPA when only minimal cortical thinning was observed and showed a good correlation with measures of disease severity. Conclusions: Cortical mean diffusivity shows promise as a sensitive biomarker for the study of the neurodegeneration-related microstructural changes in PPA.
AB - Background: Cortical mean diffusivity is a novel imaging metric sensitive to early changes in neurodegenerative syndromes. Higher cortical mean diffusivity values reflect microstructural disorganization and have been proposed as a sensitive biomarker that might antedate macroscopic cortical changes. We aimed to test the hypothesis that cortical mean diffusivity is more sensitive than cortical thickness to detect cortical changes in primary progressive aphasia (PPA). Methods: In this multicenter, case-control study, we recruited 120 patients with PPA (52 non-fluent, 31 semantic, and 32 logopenic variants; and 5 GRN-related PPA) as well as 89 controls from three centers. The 3-Tesla MRI protocol included structural and diffusion-weighted sequences. Disease severity was assessed with the Clinical Dementia Rating scale. Cortical thickness and cortical mean diffusivity were computed using a surface-based approach. Results: The comparison between each PPA variant and controls revealed cortical mean diffusivity increases and cortical thinning in overlapping regions, reflecting the canonical loci of neurodegeneration of each variant. Importantly, cortical mean diffusivity increases also expanded to other PPA-related areas and correlated with disease severity in all PPA groups. Cortical mean diffusivity was also increased in patients with very mild PPA when only minimal cortical thinning was observed and showed a good correlation with measures of disease severity. Conclusions: Cortical mean diffusivity shows promise as a sensitive biomarker for the study of the neurodegeneration-related microstructural changes in PPA.
KW - Difusion
KW - Magnetic resonance
KW - Primary progressive aphasia
KW - Alzheimer's disease
KW - Frontotemporal lobar degeneration
U2 - 10.1186/s13195-022-00974-0
DO - 10.1186/s13195-022-00974-0
M3 - Article
C2 - 35139897
SN - 1758-9193
VL - 14
JO - Alzheimer's Research and Therapy
JF - Alzheimer's Research and Therapy
IS - 1
ER -